Education
About Us
Working with TipRanks
Follow Us
Martin Mackay Insider Profile
4 Followers
Martin Mackay, EVP & Global Head of R&D at Alexion Pharmaceuticals, holds 9.96K shares in Springworks Therapeutics (Ticker: SWTX), holds 12.53K shares in Charles River Labs (Ticker: CRL), holds 719.13K shares in Rallybio (Ticker: RLYB).
Martin Mackay Alexion Pharmaceuticals (ALXN)EVP & Global Head of R&D
Alexion Pharmaceuticals (ALXN)
EVP & Global Head of R&D
Ranked #12,893 out of 100,956 Corporate Insiders
Profitable Transactions
11 out of 14 Profitable Transactions
Average Return
+9.50%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Martin Mackay holds in companies
Most Profitable Insider Trade
Stock:
Alexion Pharmaceuticals
(ALXN)
(ALXN)
Rating:Informative Sell
Date:Aug 05, 2015 - Aug 05, 2016
Return:+30.70%
The most profitable trade made by Martin Mackay
Martin Mackay's Trading History
Alexion Pharmaceuticals
Mar 01, 2017
―
Uninformative Buy
―
$7.44M
Charles River Labs
May 15, 2024
Director
Uninformative Buy
212.65K
$2.20M
5:01 Acquisition Corp Class A
―
―
―
―
Rallybio
Jan 12, 2022
Director
Uninformative Buy
―
$535.03K
Springworks Therapeutics
Jul 30, 2024
Director
Uninformative Buy
―
$493.67K
Pfizer
Mar 01, 2010
SVP
Uninformative Buy
―
$10.40M
List of latest transactions for each holding click on a transaction to see Martin Mackay's performance on stock
You May Also Like
Martin Mackay insider profile FAQ
What is the percentage of profitable transactions made by Martin Mackay?
The percentage of profitable transactions made by Martin Mackay is 79%.
What is the average return per transaction made by Martin Mackay?
The average return per transaction made by Martin Mackay is 9.50%.
What stocks does Martin Mackay hold?
Martin Mackay holds: ALXN, CRL, FVAM, RLYB, SWTX, PFE stocks.
What was Martin Mackay’s latest transaction?
Martin Mackay latest transaction was an Uninformative Buy of ―.
What was Martin Mackay's most profitable transaction?
Martin Mackay’s most profitable transaction was an Informative Sell of ALXN stock on August 5, 2015. The return on the trade was 30.70%.
What is Martin Mackay's role in Alexion Pharmaceuticals?
Martin Mackay's role in Alexion Pharmaceuticals is EVP & Global Head of R&D.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.